



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/481,733	01/11/2000	PATRICK V. WARREN	DIVER1240-5	6043
20985	7590	12/31/2003	EXAMINER	
FISH & RICHARDSON, PC 12390 EL CAMINO REAL SAN DIEGO, CA 92130-2081			SLOBODYANSKY, ELIZABETH	
		ART UNIT	PAPER NUMBER	
		1652		

DATE MAILED: 12/31/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/481,733	WARREN ET AL.
	Examiner Elizabeth Slobodyansky	Art Unit 1652
-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --		
Period for Reply <p>A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.</p> <ul style="list-style-type: none"> - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). 		
Status <p>1)<input checked="" type="checkbox"/> Responsive to communication(s) filed on <u>15 September 2003</u>.</p> <p>2a)<input type="checkbox"/> This action is FINAL. 2b)<input type="checkbox"/> This action is non-final.</p> <p>3)<input type="checkbox"/> Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i>, 1935 C.D. 11, 453 O.G. 213.</p>		
Disposition of Claims <p>4)<input checked="" type="checkbox"/> Claim(s) <u>1-14 and 17-57</u> is/are pending in the application.</p> <p>4a) Of the above claim(s) _____ is/are withdrawn from consideration.</p> <p>5)<input type="checkbox"/> Claim(s) _____ is/are allowed.</p> <p>6)<input type="checkbox"/> Claim(s) _____ is/are rejected.</p> <p>7)<input type="checkbox"/> Claim(s) _____ is/are objected to.</p> <p>8)<input checked="" type="checkbox"/> Claim(s) <u>1-14 and 17-57</u> are subject to restriction and/or election requirement.</p>		
Application Papers <p>9)<input type="checkbox"/> The specification is objected to by the Examiner.</p> <p>10)<input type="checkbox"/> The drawing(s) filed on _____ is/are: a)<input type="checkbox"/> accepted or b)<input type="checkbox"/> objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).</p> <p>11)<input type="checkbox"/> The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.</p>		
Priority under 35 U.S.C. §§ 119 and 120 <p>12)<input type="checkbox"/> Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)<input type="checkbox"/> All b)<input type="checkbox"/> Some * c)<input type="checkbox"/> None of: 1.<input type="checkbox"/> Certified copies of the priority documents have been received. 2.<input type="checkbox"/> Certified copies of the priority documents have been received in Application No. _____. 3.<input type="checkbox"/> Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</p> <p>* See the attached detailed Office action for a list of the certified copies not received.</p> <p>13)<input type="checkbox"/> Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. a)<input type="checkbox"/> The translation of the foreign language provisional application has been received.</p> <p>14)<input type="checkbox"/> Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.</p>		
Attachment(s) <p>1)<input type="checkbox"/> Notice of References Cited (PTO-892)</p> <p>2)<input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)</p> <p>3)<input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____</p> <p>4)<input type="checkbox"/> Interview Summary (PTO-413) Paper No(s) _____</p> <p>5)<input type="checkbox"/> Notice of Informal Patent Application (PTO-152)</p> <p>6)<input type="checkbox"/> Other: _____</p>		

Art Unit: 1652

DETAILED ACTION

The amendment filed September 15, 2003 amending claims 1-13 and 17-37 and adding claims 40-57 has been entered.

The Declaration under 37 C.F.R. § 1.132 by Dr. David Weiner filed September 15, 2003 has been entered.

Claims 1-14 and 17-57 are pending.

Upon further consideration in view of the amendment the following restriction is required.

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-3, 12-14, 17-24, 35-57 (all in part) and claims 4, 25, drawn to a polynucleotide encoding an aspartate transaminase of SEQ ID NO:25, a probe and a method of making thereof, classified in class 435, subclass 193.
- II. Claims 1-3, 12-14, 17-24, 35-57 (all in part) and claims 5, 26, drawn to a polynucleotide encoding an aspartate transaminase of SEQ ID NO:26, a probe and a method of making thereof, classified in class 435, subclass 193.

Art Unit: 1652

- III. Claims 1-3, 12-14, 17-24, 35-57 (all in part) and claims 6, 27, drawn to a polynucleotide encoding an adenosyl-8-amino-7-oxononanoate aminotransferase of SEQ ID NO:27, a probe and a method of making thereof, classified in class 435, subclass 193.
- IV. Claims 1-3, 12-14, 17-24, 35-57 (all in part) and claims 7, 28, drawn to a polynucleotide encoding an acetylcarnitine aminotransferase of SEQ ID NO:28, a probe and a method of making thereof, classified in class 435, subclass 193.
- V. Claims 1-3, 12-14, 17-24, 35-57 (all in part) and claims 8, 29, drawn to a polynucleotide encoding an aspartate aminotransferase of SEQ ID NO:29, a probe and a method of making thereof, classified in class 435, subclass 193.
- VI. Claims 1-3, 12-14, 17-24, 35-57 (all in part) and claims 9, 30, drawn to a polynucleotide encoding a glucosamine:fructose-6-phosphate aminotransferase of SEQ ID NO:30, a probe and a method of making thereof, classified in class 435, subclass 193.
- VII. Claims 1-3, 12-14, 17-24, 35-57 (all in part) and claims 10, 31, drawn to a polynucleotide encoding a histidinol-phosphate aminotransferase of SEQ ID NO:31, a probe and a method of making thereof, classified in class 435, subclass 193.

Art Unit: 1652

VIII. Claims 1-3, 12-14, 17-24, 35-57 (all in part) and claims 11, 32, drawn to a polynucleotide encoding a branched chain aminotransferase of SEQ ID NO:32, a probe and a method of making thereof, classified in class 435, subclass 193.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-VIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions I-VIII are drawn to polynucleotides encoding aminotransferases/transaminases having different structures and different functions and thus, different utilities. Therefore, where structural identity is required, such as for hybridization or expression, the different sequences have different effects.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

A telephone call was made to Mr. Gregory Einhorn on December 22, 2003 to request an oral election to the above restriction requirement, but did not result in an election being made.

Art Unit: 1652


Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(l).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth Slobodyansky whose telephone number is (703) 306-3222. The examiner can normally be reached Monday through Friday from 9:30 AM to 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Ponnathapura Achutamurthy, can be reached at (703) 308-3804. The FAX phone number for Technology Center 1600 is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Center receptionist whose telephone number is (703) 308-0196.



Elizabeth Slobodyansky, PhD
Primary Examiner

December 22, 2003